Journal of Nanomaterials & Molecular NanotechnologyISSN: 2324-8777

Reach Us +18507546199

Research Article, J Nanomater Mol Nanotechnol Vol: 3 Issue: 1

IG-001 - A Non-Biologic Nanoparticle Paclitaxel for the Treatment of Solid Tumors

Kouros Motamed*, Yin Goodman, Larn Hwang, Chao Hsiao and Vuong Trieu
IGDRASOL Inc. One Technology Dr. Suite J-729, Irvine, CA, USA
Corresponding author : Dr. Kouros Motamed
IGDRASOL Inc. One Technology Dr. Suite J-729, Irvine, CA 92618, USA
Tel: 1-949-988-7920; Fax: 1-949-988-7927
E-mail: [email protected]
Received: October 22, 2013 Accepted: January 07, 2014 Published: January 07, 2014
Citation: Motamed K, Goodman Y, Hwang L, Hsiao C, Trieu V (2014) IG-001 - A Non-Biologic Nanoparticle Paclitaxel for the Treatment of Solid Tumors. J Nanomater Mol Nanotechnol 3:1. doi:10.4172/2324-8777.1000136

Abstract

IG-001 - A Non-Biologic Nanoparticle Paclitaxel for the Treatment of Solid Tumors

nab-paclitaxel (Abraxane®)—a Cremophor-free, albumin-bound, nanoparticle form of paclitaxel—though a breakthrough in paclitaxel formulation, has inherent problems associated with any biologics. IG-001 (Genexol-PM®), a polymeric micellar formulation forms nanoparticles with paclitaxel containing a hydrophobic core and a hydrophilic shell and is being developed as the next generation nanoparticle paclitaxel. Its target indications are solid tumors including Breast, Lung, Ovarian, Bladder, Melanoma and Pancreatic cancers. Similar to nab-paclitaxel, due to its very fast dissolution in plasma, high tumor/plasma ratio, and dose-proportional PK, IG-001 is a superior alternative to Taxol®. Moreover, despite a lack of serum albumin in its formulation, IG-001 takes full advantage of its ability to rapidly deliver paclitaxel to the targeted tissue via an albuminmediated transport, as previously described for nab-paclitaxel.

Keywords:

Track Your Manuscript

Share This Page

Associations